Back to News
Activism

Drinks With The Deal: Eduardo Gallardo of Gibson Dunn

|
Published: December 19th, 2021
Eduardo Gallardo, co-chair of M&A and chair of the activist defense group at Gibson Dunn, discusses the universal proxy, the Williams case and more on this week's Drinks With The Deal podcast.

Eduardo Gallardo of Gibson, Dunn & Crutcher LLP believes the effects of recently adopted universal proxy card rules by the Securities and Exchange Commission will be significant.

“I think it’s a big deal,” he said on this week’s Drinks With The Deal podcast. “This is going to incentivize more activists to launch campaigns because their odds will be better of getting one or two members of their dissident slate on the board.”

On Nov. 17, the SEC approved rules giving institutional investors more flexibility to pick and choose incumbent and dissident director candidates on a universal proxy card.

“It’s going to increase the number of contests, it’s going to put a floor of one on any settlement discussions, and I think you should not understate the role it’s going to play with [proxy advisers Institutional Shareholder Services Inc. and Glass, Lewis & Co. LLC],” he said.

Gallardo discussed other aspects of shareholder activism on the podcast, including the lessons of the decision earlier this year in which the Delaware Court of Chancery ordered the board of Williams Cos. (WMB) to redeem a poison pill it installed at the start of the pandemic as well as the effect of ESG on how a board should consider shareholder value.

Here’s the podcast:

More podcasts from The Deal are available on iTunesSpotify and on TheDeal.com.

More From Activism

Activism

Activist Spotlight: Share Lending Under Fire

By Ronald Orol
|
Published: December 17th, 2021
A regulatory proposal requiring big index fund managers and other institutional investors to disclose share lending programs could upend short-selling activism and drive an uptick in ESG voting.
Activism

Drinks With The Deal: Willkie's Tariq Mundiya

By David Marcus
|
Published: December 2nd, 2021
Willkie head of litigation Tariq Mundiya discusses the Williams poison pill case from earlier this year as well as the CytoDyn decision and the evolution of Delaware's Caremark doctrine in this week's Drinks With The Deal podcast.